Exane Derivatives’s Futu Holdings FUTU Stock Holding History

Exane Derivatives’s Portfolio FUTU Stock Details FUTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,710	Closed	-$429K	–	914
2021 Q3	$429K	Buy	4,710 +1,653	+54%	+$182K	0.1%	210
2021 Q2	$413K	Buy	3,057 +1,030	+51%	+$150K	0.09%	226
2021 Q1	$322K	Sell	2,027 -10,416	-84%	-$1.29M	0.09%	206
2020 Q4	$569K	Buy	+12,443	New	+$468K	0.17%	126

Other funds holding FUTU

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Tiger Global Management New York $24B AUM 39.59% 1-Year Est. Return

AMH

Aspex Management (HK) Central, Hong Kong $8.89B AUM 39.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Exane Derivatives's FUTU Position: Q4 2021 in Review

Exane Derivatives sold out of Futu Holdings (FUTU) in Q4 2021, closing a stake of 4,710 shares — an estimated $429K sold.

Exane Derivatives first reported a position in FUTU in Q4 2020 and held it in 4 quarters. The position peaked at $569K in Q4 2020. 178 funds tracked by Wall St. Rank hold FUTU as of Q4 2021.

Exane Derivatives reported no remaining Futu Holdings position as of Q4 2021 after selling out during the quarter.
Exane Derivatives sold 4,710 Futu Holdings shares in Q4 2021, an estimated $429K.
Exane Derivatives first reported a position in Futu Holdings in Q4 2020 and held it in 4 quarters.
Exane Derivatives's Futu Holdings position peaked at $569K in Q4 2020.
178 funds tracked by Wall St. Rank held Futu Holdings as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.